Material and methods: We tested insulin-glucose infusion as soon as possible after onset of AMI followed by ibng-term multi dose insulin in a prospective rendemlsed study (DIGAMI) recruiting 620 diabetic pat with AML Half of the pat served as a control group (CG) while the remaining subjects constituted an insulin treatred group (IG) . Data are from one year of follow up.
Results: One year mortality decreased from 26=/0 in the CG to 19=/o in the IG (p < 0.05). The effect was most pronounced in diabetics without previous insulin and at low cardiovascular risk (reduction = 52%; < 0.02). The most frequent cause of mortality was congestive heart failure (CHF), Cardiovascular mortality (CHF, fatal rainfamtion, sudden death, stroke) tended to be less frequent in the IG. The two groups did differ as regards need for revascularication or hospital care during the year of follow up. Rainfarction was 53 (28% fatal) in the IG vs 55 (45% fatal) in CG (NS). In a multivariate analysis age, previous CHF, admission blood glucose and previous insulin therapy independently predicted one year mortality. Metabolic control at admission predicted mortality in CG but not in IG. Concomitant beta blockade was a predictor for survival among CG whereas thmmbolysfs was most efficient in IG. GISSI-3, ISIS-4, and CCS-1 trials showed a mortality reduction with an early (within 24-36 h) treatment with ACE-inhibitors (ACE-i) of unsaiectad 10ts with AML In these trials a significant reduction in mortality was already evident in the first 5 days of treatment. In pts enrolled in the GISSI-3 study, we evaluated early (0 to 5 days) mortality in lisinopdl (L) and no-lisinopril (no-L) treated pts, split by subgroups at different baseline risk. The trend in early mortality reduction was consistent in all subgroups at different risk profile, with a greater absolute benefit in the subgreuns at higher risk. Analyzing the time course of the L effect split by Killip class at entry, an early benefit from L treatment was observed either in patients in Killip class 1 or in those in Killip class 2 or 3. From day 6 to 42, no further benefit could be seen in lots in Killip class f, while Killip class 2 or 3 pts showed, as expected, a further late mortality reduction (18 lives saved per 1000), being these patients similar to those randomized in the AIR; study. These findings support an early treatment with ACE-i of relatively unselected pts with MI and its continuation for a long period of time only in those with post-AMI left ventricular failure and/or dysfunction. Further investigations are needed to explain the mechanisms underlying the early benefit, which appears different from and complementary to the favourabte modifications of ventrlcular remodelling induced by ACE-L Effects on Venlricular Arrhythmlas of an Early Uainopdl Treatment In Patients With Acute Myocardial Infarction: The GISSI-3 Experience Aldo P. Maggioni, Fabrlzio Pizzetti, Eugenio Santoro, Roberto Latini, Giulio Zuanetti, MarlaGrazia Frenzosi, on behalf of the GISSI.3
Conclusion
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The activation of renin-angiotensin-aldosterone system after myocardial infarction (MI) can increase frequency and complexity of ventrlcular arrbythmias (VA) after MI. The effects of a lisinopdl (L) treatmenL started in GISSI-3 study within 24 h from symptom onset, was evaluated on (a) life-threatening VA in the 18895 pts with complete in-hospital data and (b) VA profile in the 12"327 pts with pre~ischarge 24 h ECG monitoring data available.
The rate of pts with In-hospital life-threatening VA and with VA at predischarge 24 hour ECG monitoring in the L and no.L groups is reported In the While L treatment did not influence the VA profile detected by pre<lischarge 24 h ECG monitoring, in-hospital life-thraatening VA ware less frequent in pts allocated to L, This "antiarrbythmib" effect of L in the early phase of MI could have contributed to the reduction of eady mortality shown with this treatment in GISSI-3 trial. In a logistic regression model, the B + I group had a significant relationship with T (p = 0.016), which became more significant after adjustment for CABG, repeat PTCA, and IABP insertion (p = 0.014). Those with Thad more groin site (68 vs 39°/°) and GU tract (10 vs 4=/o) bleeding and hematemeais (10 vs 0%), but no intracranial hemorrhages or thromboses. In conclusion, we found a small but increased likelihood of developing Tin patients receiving c7E3, particularly a + I, Among all patients, c7E3 was associated with reduced ischemib complications; however, those who developed Twere at increased risk of developing iechemia-associated morbidity and mortality.
